Onconase, Amphinase 2 show positive results for SARS virus: Tamir Biotechnology

Download PDF Copy

Jul 22 2010

Tamir Biotechnology, Inc. (formerly Alfacell Corporation) (OTCBB:ACEL) announced today that scientists supported by the National Institute of Allergy and Infectious Diseases (NIAID) confirmed that testing of two (2) of the company's compounds Onconase^® (Ranpirnase), and recombinant Amphinase 2 showed positive in vitro results for Severe Acute Respiratory Syndrome, also known as (SARS) virus.

In order to determine the effectiveness of a compound, NIAID uses a Selectivity Index (SI). The SI measures EC50 (50% virus-inhibitory (effective) concentration and EC90 (90%) cell inhibitory (cytotoxic) concentration determined in stationary cells.

"Many companies spend years in research and development and untold millions in the hope of developing a compound capable of demonstrating anti viral activity against a single virus. This week we've been able to report positive anti viral activity in Dengue stated Charles Muniz, Chief Executive Officer of Tamir.

SOURCE Tamir Biotechnology, Inc.

Posted in: Disease/Infection News | Pharmaceutical News

Comments (0)

Download PDF Copy

Suggested Reading

New computer-driven method helps understand how membrane proteins work at the atomic level

AI-designed proteins revolutionize gene editing precision and safety

AI model predicts flu vaccine strains more accurately than WHO

Taste-based flu test that detects infection within minutes

Herpes virus infection linked to higher Alzheimer’s risk, study shows antiherpetic drugs may help

Electromagnetic waves disrupt SARS-CoV-2 spike protein and lower infectivity

MPXV virus lingers on hospital surfaces after patient stays

Nirsevimab sharply cuts RSV hospitalizations in U.S. infants during the 2024–2025 season

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.

Post a new comment

(Logout)

Post

Sign in to keep reading

We're committed to providing free access to quality science. By registering and providing insight into your preferences you're joining a community of over 1m science interested individuals and help us to provide you with insightful content whilst keeping our service free.